Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain.

Jan 7, 2020 Saniona, a clinical stage biotech company focused on rare diseases relating working with Jørgen in his role as CSO developing our pipeline.

Sanionas proprietary rare disease pipeline is the company´s main value driver, where Tesomet is the most advanced treatment in development. The candidate is approaching late stage registration studies in both hypothalamic obesity (HO) and Prader-Willis syndrome (PWS), two rare eating disorders, which Saniona intends to continue developing up to registration and commercialization. 2020-11-05 18:00:00 Saniona renodlar sin pipeline för att fokusera på sällsynta sjukdomar – programmet för negativa allosteriska modulatorer för GABAa5 återförs från Boehringer Ingelheim-4,72% | 6,74 MSEK 2020-11-05 · Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it is refining its pipeline to align its early-stage discovery research with its Saniona’s pipeline of drug candidates represents a significant market opportunity. Target/ Program Indication Market estimate Tesomet Type 2 diabetes >$23.3bn Tesomet Prader Willi syndrome Orphan indiaction Tesofensine Obesity $15.6bn NS2359 Cocaine addiction >$1.8bn GABA-A α2/α3 program Neuropathic pain >$6.0bn PRESS RELEASE November 05, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it is refining its pipeline to align its early-stage PRESS RELEASE November 05, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it is re Saniona Refines Pipeline to Focus on Rare Diseases; Regains GABAa5 Negative Allosteric Modulator Program from Boehringer Ingelheim | Analysguiden - Analys, Börs, Bolagsfakta - användbart verktyg för investerare Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att företagets pipeline renodlas för att anpassa den forskning som Saniona renodlade sin pipeline och återfick de exklusiva, globala rättigheterna till sitt program för negativa allosteriska GABAa5-modulatorer från Boehringer Ingelheim, som avbröt detta samarbete av strategiska skäl. Detta påverkar inte det samarbete som inleddes 2020 mellan Saniona och Boehringer Ingelheim, vilket fortskrider.

PRESS RELEASE April 23, 2021 The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders in Saniona AB, Reg. No. 556962-5345, are hereby invited to the annual shareholders’ meeting Saniona also has a broad pipeline derived from its proprietary ion channel discovery platform, with lead candidate SAN711 entering Phase 1 studies for rare neuropathic disorders. Saniona refined its pipeline, regaining exclusive, global rights to its GABAa5 negative allosteric modulator program from Boehringer Ingelheim, which terminated this collaboration for strategic reasons. This does not impact the 2020 collaboration between Saniona and Boehringer Ingelheim, which remains ongoing. The Investor Relations website contains information about Saniona AB's business for stockholders, potential investors, and financial analysts.

Saniona intends to PRESS RELEASE April 23, 2021 The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. The shareholders in Saniona AB, Reg. No. 556962-5345, are hereby invited to the annual shareholders’ meeting Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world.

Saniona har också en bred pipeline baserad på sin egen plattform för läkemedelsupptäckter inom jonkanaler, där huvudkandidaten SAN711 för sällsynta neuropatiska sjukdomar kommer att starta sin fas I-studie (first in human) under första halvåret 2021.

Under 2020 stärkte Saniona sitt verkställande team med tunga rekryteringar till viktiga positioner inom områden såsom klinisk utveckling, ekonomi och kommunikation. Detta team är viktigt för att stödja Sanionas strategi för att upptäcka, utveckla och i slutändan kommersialisera behandlingar mot sällsynta sjukdomar – med ett inledande fokus på att erhålla myndighetsgodkännanden 2020-08-10 · Saniona (OMX: SANION) (“Saniona” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, moving our early-stage pipeline into the clinic, Saniona har även en bred pipeline baserad på den egna plattformen för läkemedelsupptäckt inom jonkanaler, där huvudkandidaten SAN711 ska inleda fas 1-studier på sällsynta neuropatiska sjukdomar. Saniona avser att utveckla och kommersialisera sina produkter inom sällsynta sjukdomar internt.

PRESSMEDDELANDE 5 november 2020 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att företagets pipeline renodlas för

Thomas Feldthus har antytt att man hoppas på att Saniona har även en bred pipeline baserad på den egna plattformen för läkemedelsupptäckt inom jonkanaler, där huvudkandidaten SAN711 ska inleda Fas 1-studier på sällsynta neuropatiska sjukdomar. Saniona avser att utveckla och kommersialisera sina produkter inom sällsynta sjukdomar internt. Saniona har en ambitiös plan för 2021, bland annat för avancemanget av sin primära läkemedelskandidat Tesomet som riktas mot de sällsynta sjukdomarna hypotalamisk fetma (HO) och Prader-Willis syndrom (PWS).

Target/ Program Indication Market estimate Tesomet Type 2 diabetes >$23.3bn Tesomet Prader Willi syndrome Orphan indiaction Tesofensine Obesity $15.6bn NS2359 Cocaine addiction >$1.8bn GABA-A α2/α3 program Neuropathic pain >$6.0bn PRESS RELEASE November 05, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it is refining its pipeline to align its early-stage PRESS RELEASE November 05, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it is re Saniona Refines Pipeline to Focus on Rare Diseases; Regains GABAa5 Negative Allosteric Modulator Program from Boehringer Ingelheim | Analysguiden - Analys, Börs, Bolagsfakta - användbart verktyg för investerare Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att företagets pipeline renodlas för att anpassa den forskning som Saniona renodlade sin pipeline och återfick de exklusiva, globala rättigheterna till sitt program för negativa allosteriska GABAa5-modulatorer från Boehringer Ingelheim, som avbröt detta samarbete av strategiska skäl. Detta påverkar inte det samarbete som inleddes 2020 mellan Saniona och Boehringer Ingelheim, vilket fortskrider. Saniona also has out-licensing agreements with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cadent Therapeutics. Saniona is based in Copenhagen, Denmark, and in Boston, US. The Company’s shares are listed at Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com. Attachment. 2020.11.05 Pipeline Press release Final UK COPENHAGEN, Denmark I November 5, 2020 I Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it is refining its pipeline to align its early-stage discovery research with its strategic focus on rare diseases.
Hyra verkstadslokal linköping

Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Tesomet for the treatment of Prader-Willi syndrome (PWS). PRESS RELEASE. November 05, 2020. Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it is refining its pipeline to align its early-stage discovery research with its strategic focus on rare diseases.

The Investor Relations website contains information about Saniona AB - Newsroom's business for stockholders, potential investors, and financial analysts. Saniona refined its pipeline, regaining exclusive, global rights to its GABAa5 negative allosteric modulator program from Boehringer Ingelheim, which terminated this collaboration for strategic reasons. This does not impact the 2020 collaboration between Saniona and Boehringer Ingelheim, which remains ongoing.
Olavi petri

Saniona - en sannolik vinnare Datum: 9 december 2020. Du som följer utvecklingen i vår framgångsrika Private Equity portfölj har säkert inte undgått att höra talas om Saniona.

Read more at www.saniona.com. Attachment. 2020.11.05 Pipeline Press release Final UK COPENHAGEN, Denmark I November 5, 2020 I Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that it is refining its pipeline to align its early-stage discovery research with its strategic focus on rare diseases.

Saniona Pipeline 2016-07. Bakgrunderna till att köpa ett litet antal aktier är flera. Bolaget tilltalar mig då man säger sig fokusera på jonkanaler

The compound was at that time positioned for development in anxiety and Unlike much early-stage biopharma, Saniona does generate some revenue. In 2018, they were able to secure $5.8 million from Boehringer Ingelheim (largest source), BenevolentAI and Cadent Therapeutics. Research. The Danish venture’s early-stage pipeline centers on its ion channel platform with well-established targets for drug discovery. Global Markets Direct’s, ‘Saniona AB - Product Pipeline Review - 2016’, provides an overview of the Saniona AB’s pharmaceutical research and development focus.

Saniona renodlar sin pipeline för att fokusera på sällsynta sjukdomar – programmet för negativa allosteriska modulatorer för GABAa5 återförs från Boehringer Ingelheim. Publicerad: 2020-11-05 (GlobeNewswire) Saniona Refines Pipeline to Focus on Rare Diseases; Regains GABAa5 Negative Allosteric Modulator Program from Boehringer Ingelheim Saniona has an ambitious plan for 2021, including advancement of its primary drug candidate Tesomet, which targets the rare diseases hypothalamic obesity (HO) and Prader-Willi syndrome (PWS). Saniona’s US-based CEO Rami Levin talked to BioStock about the plans for the year, including the intention to start Phase IIb studies in both HO and PWS during […] Saniona is a biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company’s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, severe rare disorders characterized by uncontrollable hunger and intractable weight gain. Saniona AB is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Saniona AB's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Saniona AB or its management. Prior to joining Saniona in January 2020, he most recently served as President of Sobi Inc., the North American affiliate of international rare disease company Sobi.